Vertex Pharmaceuticals (VRTX) R&D In Process (2021 - 2026)
Vertex Pharmaceuticals' quarterly R&D In Process came in at $500000.0 in Q1 2026, down 97.47% year-on-year from $19.8 million in Q1 2025, and down 99.12% quarter-over-quarter from $56.5 million in Q4 2025.
Vertex Pharmaceuticals has reported R&D In Process for 6 years, with the latest figure at $500000.0 in Q1 2026.
- For the quarter ending Q1 2026, R&D In Process fell 97.47% year-over-year to $500000.0; the trailing twelve-month figure through Mar 2026 stood at $113.7 million (down 97.51% YoY), and the FY2025 full-year result was $133.0 million, down 97.13% from the prior year.
- R&D In Process for Q1 2026 stood at $500000.0, down from $56.5 million in the prior quarter.
- The five-year high for R&D In Process was $4.4 billion in Q2 2024, with the low at $500000.0 in Q1 2026.
- Average R&D In Process over 5 years is $301.1 million, with a median of $51.7 million recorded in 2023.
- Year-over-year, R&D In Process soared 3881.9% in 2024 and slumped 99.95% in 2025.
- Tracing VRTX's R&D In Process over 5 years: stood at $22.6 million in 2022, then slipped by 21.24% to $17.8 million in 2023, then soared by 621.35% to $128.4 million in 2024, then sank by 56.0% to $56.5 million in 2025, then slumped by 99.12% to $500000.0 in 2026.
- The last three R&D In Process figures came in at $500000.0 (Q1 2026), $56.5 million (Q4 2025), and $54.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 56.50 Mn |
| Sep 30, 2025 | 54.50 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 19.80 Mn |
| Dec 31, 2024 | 128.40 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 4.40 Bn |
| Mar 31, 2024 | 76.80 Mn |
| Dec 31, 2023 | 17.80 Mn |
| Sep 30, 2023 | 51.70 Mn |
| Jun 30, 2023 | 110.50 Mn |
| Mar 31, 2023 | 70.00 Mn |
| Dec 31, 2022 | 22.60 Mn |
| Sep 30, 2022 | 29.00 Mn |
| Jun 30, 2022 | 61.90 Mn |
| Mar 31, 2022 | 2.00 Mn |
| Dec 31, 2021 | 126.50 Mn |
| Sep 30, 2021 | 26.70 Mn |
| Jun 30, 2021 | 958.40 Mn |